Lista de obras -

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

artículo científico publicado en 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation ⬇️

artículo científico publicado el 26 de octubre de 2012

A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer

scientific article published on 01 January 2007

A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer

artículo científico publicado en 2007

A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.

artículo científico publicado en 2012

A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer

scientific article published on 04 September 2019

A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma

scientific article published on 19 February 2020

A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study

artículo científico publicado en 2020

A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers ⬇️

artículo científico publicado el 17 de febrero de 2011

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

artículo científico publicado en 2014

A value framework in head and neck cancer care

artículo científico publicado en 2014

AHNS Series - Do you know your guidelines? Principles of treatment for nasopharyngeal cancer: A review of the National Comprehensive Cancer Network guidelines

artículo científico publicado en 2016

Abstract 1847: Influence of growth factors on resistance to EGFR inhibitor treatment in HNSCC - Temsirolimus as a potential concept

Abstract 2746: An evaluation of poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer

Abstract 2832: Fibroblast growth factors in head and neck cancer: Genetic alterations and therapeutic targeting with ponatinib

Abstract 4919: Pathway profiling of head and neck cancer cell lines

Abstract LB-398: Detection of copy number alterations in 124 head and neck squamous cell carcinomas using the Nanostring nCounter assay

Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies ⬇️

artículo científico publicado el 26 de julio de 2011

An Immunogenomic Investigation of Oral Cavity Squamous Cell Carcinoma in Patients Aged 45 Years and Younger

scientific article published on 16 April 2020

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

artículo científico publicado en 2016

Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck

artículo científico publicado en 2017

Chemoradiation for patients with large‐volume laryngeal cancers ⬇️

artículo científico publicado el 3 de noviembre de 2011

Chemoradiotherapy for locally advanced head and neck cancer

artículo científico publicado en 2007

Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays

artículo científico publicado en 2016

Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)

scientific article published on 03 April 2019

Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades

artículo científico publicado en 2014

DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer

artículo científico publicado en 2014

Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience

scientific article published on 16 March 2018

Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions

artículo científico publicado en 2020

Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer

scientific article published on 10 June 2019

Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Post-Treatment Functional Outcomes

scientific article published on 17 April 2020

EGFR-directed treatments in SCCHN.

artículo científico publicado en 2013

Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin ⬇️

artículo científico publicado el 24 de marzo de 2011

Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis

artículo científico publicado en 2013

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

artículo científico publicado en 2018

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

artículo científico publicado en 2009

Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab

artículo científico publicado en 2015

Expression and mutational analysis of MET in human solid cancers

artículo científico publicado en 2008

Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma

artículo científico

Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.

artículo científico publicado en 2016

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma

artículo científico publicado en 2006

Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation

artículo científico publicado en 2006

Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors

artículo científico publicado en 2015

Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.

artículo científico publicado en 2015

Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.

artículo científico publicado en 2015

Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas.

artículo científico publicado en 2016

HPV-Associated Head and Neck Cancer

artículo científico publicado en 2015

HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas

artículo científico publicado en 2013

How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?

article by Petr Szturz et al published 10 July 2017 in Journal of Clinical Oncology

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.

artículo científico publicado en 2017

Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy

artículo científico publicado en 2019

Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma

scholarly article by Lili Ren et al published 2019 in OncoImmunology

Immune profiles in primary squamous cell carcinoma of the head and neck

scientific article published on 12 July 2019

Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options

artículo científico publicado en 2017

Impact of warm ischemia on phosphorylated biomarkers in head and neck squamous cell carcinoma

artículo científico publicado en 2014

Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes

artículo científico publicado en 2014

Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas

artículo científico publicado en 2014

MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma

artículo científico publicado en 2014

MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer

scientific article published on January 2009

Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix

artículo científico publicado en 2016

Molecular pathways in head and neck cancer: EGFR, PI3K, and more

artículo científico publicado en 2013

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition ⬇️

artículo científico publicado el 14 de noviembre de 2012

Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic

artículo científico publicado en 2011

Molecular targeted therapies in head and neck cancer--an update of recent developments-

scientific article published on 14 April 2010

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer

scientific article published on 01 October 2019

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer

scientific article published on 01 February 2019

OPTIMA—A Phase 2 Trial of Induction Chemotherapy Response-Stratified Radiation Therapy Dose and Volume De-escalation for HPV+ Oropharyngeal Cancer: Efficacy, Toxicity, and HPV Subtype Analysis

article

Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA.

artículo científico publicado en 2013

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

artículo científico publicado en 2017

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy

artículo científico publicado en 2018

Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion

artículo científico publicado en 2008

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

artículo científico publicado en 2017

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

artículo científico publicado en 2016

Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer

artículo científico publicado en 2008

Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck ⬇️

artículo científico publicado el 17 de abril de 2012

Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck ⬇️

artículo científico publicado el 8 de marzo de 2011

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

artículo científico publicado en 2012

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer

artículo científico publicado en 2014

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

artículo científico publicado en 2016

Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer

artículo científico publicado en 2014

Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation ⬇️

artículo científico publicado el 13 de junio de 2011

Prognostic value of pre-treatment CT texture analysis in combination with change in size of the primary tumor in response to induction chemotherapy for HPV-positive oropharyngeal squamous cell carcinoma

Protein kinase C beta in malignant pleural mesothelioma

artículo científico publicado en 2008

RON(MST1R)is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma ⬇️

artículo científico publicado el 1 de julio de 2011

Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma

artículo científico publicado en 2014

Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors

artículo científico publicado en 2015

Reply to s. Chakraborty et al

artículo científico publicado en 2015

Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer

artículo científico publicado en 2016

Role of c-MET in upper aerodigestive malignancies--from biology to novel therapies

artículo científico publicado en 2005

Role of dental hardware in oral cavity squamous cell carcinoma in the low-risk nonsmoker nondrinker population

artículo científico publicado en 2018

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

artículo científico publicado en 2016

Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those of in vitro expanded populations in head and neck cancer

artículo científico publicado en 2017

Single sample expression-anchored mechanisms predict survival in head and neck cancer

artículo científico publicado en 2012

Somatic mitochondrial mutation discovery using ultra-deep sequencing of the mitochondrial genome reveals spatial tumor heterogeneity in head and neck squamous cell carcinoma

artículo científico publicado en 2019

State-of-the-art management of locally advanced head and neck cancer

artículo científico publicado en 2005

Targeting angiogenesis in head and neck cancer

artículo científico publicado en 2008

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma

artículo científico publicado en 2009

The chemoradiation paradigm in head and neck cancer

artículo científico publicado en 2007

The concurrent chemoradiation paradigm--general principles

artículo científico publicado en 2007

Ties that bind: p16 as a prognostic biomarker and the need for high-accuracy human papillomavirus testing

artículo científico publicado en 2014

Time to Debunk an Urban Myth? The "Abscopal Effect" With Radiation and Anti-PD-1

artículo científico publicado en 2020

Variations in HPV function are associated with survival in squamous cell carcinoma

artículo científico publicado en 2019

WHSC1 promotes oncogenesis through regulation of NIMA-related kinase-7 in squamous cell carcinoma of the head and neck.

artículo científico publicado en 2014

mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas

artículo científico publicado en 2012

Lista de obras de

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation ⬇️

A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer

A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer

A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.

A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer

A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma

A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study

A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers ⬇️

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

A value framework in head and neck cancer care

AHNS Series - Do you know your guidelines? Principles of treatment for nasopharyngeal cancer: A review of the National Comprehensive Cancer Network guidelines

Abstract 1847: Influence of growth factors on resistance to EGFR inhibitor treatment in HNSCC - Temsirolimus as a potential concept

Abstract 2746: An evaluation of poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer

Abstract 2832: Fibroblast growth factors in head and neck cancer: Genetic alterations and therapeutic targeting with ponatinib

Abstract 4919: Pathway profiling of head and neck cancer cell lines

Abstract LB-398: Detection of copy number alterations in 124 head and neck squamous cell carcinomas using the Nanostring nCounter assay

Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies ⬇️

An Immunogenomic Investigation of Oral Cavity Squamous Cell Carcinoma in Patients Aged 45 Years and Younger

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck

Chemoradiation for patients with large‐volume laryngeal cancers ⬇️

Chemoradiotherapy for locally advanced head and neck cancer

Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays

Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)

Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades

DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer

Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience

Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions

Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer

Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Post-Treatment Functional Outcomes

EGFR-directed treatments in SCCHN.

Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin ⬇️

Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab

Expression and mutational analysis of MET in human solid cancers

Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma

Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma

Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation

Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors

Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.

Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.

Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas.

HPV-Associated Head and Neck Cancer

HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas

How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.

Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy

Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma

Immune profiles in primary squamous cell carcinoma of the head and neck

Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options

Impact of warm ischemia on phosphorylated biomarkers in head and neck squamous cell carcinoma

Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes

Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas

MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma

MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer

Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix

Molecular pathways in head and neck cancer: EGFR, PI3K, and more

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition ⬇️

Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic

Molecular targeted therapies in head and neck cancer--an update of recent developments-

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer

OPTIMA—A Phase 2 Trial of Induction Chemotherapy Response-Stratified Radiation Therapy Dose and Volume De-escalation for HPV+ Oropharyngeal Cancer: Efficacy, Toxicity, and HPV Subtype Analysis

Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA.

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy

Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer

Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck ⬇️

Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck ⬇️

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer